Geron Corp (GERN): Shareholders' Equity
$225.87M
As of 2025-12-31
$218.61M
As of 2026-06-30
+41.3%
3-year compound annual growth
+1.4%
5-year compound annual growth
+4.7%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $225.87M | -19.4% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $280.32M | +13.1% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $247.95M | +209.9% | 2026-03-02, Balance as of period end |
| 2022-12-31 | $80.00M | -36.7% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $126.42M | -40.1% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $210.95M | +56.1% | 2023-03-16, Balance as of period end |
| 2019-12-31 | $135.16M | -24.0% | 2022-03-10, Balance as of period end |
| 2018-12-31 | $177.73M | +71.2% | 2021-03-11, Balance as of period end |
| 2017-12-31 | $103.80M | -15.2% | 2020-03-12, Balance as of period end |
| 2016-12-31 | $122.38M | -13.9% | 2019-03-07, Balance as of period end |
| 2015-12-31 | $142.13M | +8.7% | 2018-03-16, Balance as of period end |
| 2014-12-31 | $130.71M | +118.7% | 2017-03-01, Balance as of period end |
| 2013-12-31 | $59.76M | -30.2% | 2016-03-10, Balance as of period end |
| 2012-12-31 | $85.65M | -41.6% | 2015-03-11, Balance as of period end |
| 2011-12-31 | $146.60M | -23.9% | 2014-03-17, Balance as of period end |
| 2010-12-31 | $192.74M | +11.7% | 2013-03-15, Balance as of period end |
| 2009-12-31 | $172.58M | n/a | 2012-03-07, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Geron Corp (GERN) | 2025-12-31 | $225.87M | -19.4% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $424.29M | -10.1% |
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $522.26M | +13.7% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $305.72M | -34.1% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $381.93M | -9.1% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $300.13M | +14.2% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $114.83M | +94.4% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $478.56M | +17.0% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $493.40M | +40.0% |
Compare GERN, LAB, EWTX, NUVB side by side · Screen every company in Pharmaceutical Preparations ↗